Upadacitinib for Moderate to Severe Crohn's Disease

Positioning in Treatment Algorithm

• The American Gastroenterological Association (AGA) guidelines suggest considering upadacitinib after failure of TNF-alpha inhibitors, providing an additional option with a novel mechanism of action for patients with moderate to severe Crohn's disease 1, 2
• For patients with primary non-response to TNF inhibitors, the AGA recommends considering upadacitinib as an alternative option, in addition to ustekinumab and vedolizumab 2, 3

Limitations and Future Directions

• Head-to-head comparisons with other biologics for Crohn's disease are lacking, and long-term safety data specific to Crohn's disease patients is still being collected, highlighting the need for further research 3